Answers are grounded in this paper and cite their sources.
Phase 2 trial shows MRD status predicts outcomes in multiple myeloma patients on lenalidomide maintenance, suggesting immune factors play a role.
Purpose: Lenalidomide maintenance is the most frequently utilized approach for newly diagnosed multiple myeloma (MM) patients following induction therapy with/without consolidative high-dose melphalan and autologous stem cell transplantation. Baseline and longitudinal measurable residual disease (MRD) negative status is a well-established positive predictive sign in lenalidomide maintenance patients. However, the clinical utility of serial MRD assessments remains uncertain, as there is no consensus on the clinical management of MRD-resurgence (MRDres) or stable remissions in patients positive for MRD. Experimental Design: Here we report the complete and final results of a phase 2, single-arm study of 5 years of continuous lenalidomide maintenance in MM patients following unrestricted upfront therapy, along with exploratory peripheral blood T cell profiling experiments performed via high-dimensional spectral cytometry. Results: Patients with MRDres had inferior PFS to those with sustained MRD-negativity at the 1- and 2-year landmarks (P=0.036, P=0.0014 respectively); however, myeloma progression only occurred within 2 years of MRDres in 36% of patients, with no progression observed in the remaining 64% of patients at last follow-up. Exploratory peripheral blood T cell profiling experiments throughout the trial period identified an immune signature of early relapse in patient cohorts both negative and positive for MRD at the start of maintenance therapy. T cell profiles enriched with activated cytotoxic effectors predicted early relapse while quiescent T cell profiles enriched with naïve T cell populations predicted durable remissions. Conclusions: This “immune-MRD” status showed predictive potential, and segregated patients with MRDres and early disease progression from patients with sustained remission despite MRDres.
No takes yet. Share an insight, caveat, or question.
Firestone et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: